Amylyx Pharmaceuticals, INC Form 4 insider transactions

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,678 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Director George M. Milne Jr. reports a gift of Amylyx Pharmaceuticals common stock, while holding a significant number of shares subject to a lock-up agreement.

Amylyx Pharmaceuticals Co-Chief Executive Officer, Justin B. Klee, sold 7,471 shares of common stock to cover tax obligations related to vesting restricted stock units.

Amylyx Pharmaceuticals Co-Chief Executive Officer, Joshua B. Cohen, sold 7,471 shares to cover tax obligations related to vesting restricted stock units.

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 5,421 shares of common stock to cover tax obligations related to vesting restricted stock units.

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, exercised stock options on November 4, 2024, acquiring 63,690 shares of common stock.

Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares of common stock on September 30, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Chief Medical Officer of Amylyx Pharmaceuticals, Camille L Bedrosian, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold shares of common stock on September 30, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 1,857 shares of common stock at a price of $1.57 on September 23, 2024.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 34,449 shares of common stock on September 12, 2024.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, recently purchased 40,000 shares of the company's common stock at an average price of $2.5342.

Director Karen Firestone increased her stake in Amylyx Pharmaceuticals by purchasing 50,000 shares of common stock at an average price of $2.1318 on September 5, 2024.

James M. Frates, CFO of Amylyx Pharmaceuticals, files an amended Form 4 to correct an overstatement of beneficially owned securities.

Director George M. Milne Jr. of Amylyx Pharmaceuticals, Inc. [AMLX] acquired 100,000 shares of common stock at an average price of $2.198 on September 3, 2024, increasing his total holdings to 858,571 shares.

Paul R. Fonteyne, a director at Amylyx Pharmaceuticals, acquired stock options for 25,000 shares on June 6, 2024.

Karen Firestone, a director at Amylyx Pharmaceuticals, reported the acquisition of a stock option to purchase 25,000 shares of common stock.

Bernhardt G. Zeiher, a director of Amylyx Pharmaceuticals, acquired stock options exercisable for 5,753 shares of common stock on June 6, 2024.

George M. Milne Jr., a director at Amylyx Pharmaceuticals, acquired 25,000 stock options on June 6, 2024.

Daphne Quimi, a director at Amylyx Pharmaceuticals, acquired stock options for 25,000 shares on June 6, 2024.

Director Daphne Quimi recently acquired additional shares of Amylyx Pharmaceuticals, signaling confidence in the company's future.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 10,455 shares of common stock at an average price of $1.8799 per share under a pre-arranged trading plan.

Chief Financial Officer James M. Frates of Amylyx Pharmaceuticals received stock options and restricted stock units, as detailed in a recent SEC filing.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, acquired stock options and restricted stock units (RSUs) as part of her compensation.

Co-CEO Justin B. Klee reports acquiring shares and stock options in Amylyx Pharmaceuticals, signaling potential confidence in the company's future.

Chief Medical Officer Camille L. Bedrosian reports acquisition of common stock and stock options in Amylyx Pharmaceuticals.